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Abstract: Human T-lymphotropic virus type I (HTLV-I) infects an estimated 15–20 million 
persons worldwide. A number of diseases have been associated with the virus including 
adult  T-cell  leukemia  (ATL),  HTLV-associated  myelopathy/tropical  spastic  paraparesis 
(HAM/TSP), HTLV-I uveitis, and HTLV-I-associated infective dermatitis. Once it was 
shown  that  there  is  an  increased  risk  for  developing  HAM/TSP  associated  with  blood 
transfusion, screening for HTLV-1 among blood banks was implemented in Japan, United 
States,  France,  and  the  Netherlands.  This  process  includes  detection  by  an  enzyme 
immunoassay (EIA) followed by a confirmatory Western blot (WB) in which recombinant 
proteins specific for HTLV-I Env glycoproteins are incorporated into WB strips. HTLV-I 
seropositive  results  are  defined  by  the  presence  of  antibodies  against  either  gp46  or 
gp62/68 (both Env protein bands) and either p19, p24, or p53 (one of the gag bands). 
HTLV-II  seropositivity  is  confirmed  by  the  presence  of  rgp46-II.  However,  numerous 
cases  have  been  documented  in  which  serum  samples  are  reactive  by  EIA,  but  an 
incomplete banding pattern is displayed by subsequent confirmatory WB. Although the 
significance  of  these  HTLV-I/II  seroindeterminates  is  unclear,  it  may  suggest  a  much 
higher incidence of exposure to HTLV-I/II than previously estimated. 
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1. Background 
The  first  detection  of  the  Human  T-lymphotropic  virus  type  I  (HTLV-I)  in  1980  marked  the 
identification  of  the  first  human  retrovirus  [1].  While  approximately  95%  of  HTLV-I  infected 
individuals will remain asymptomatic for their lifetimes, roughly 5% of these patients will develop 
disease.  Numerous  diseases  have  been  associated  with  the  virus,  including  adult  T-cell  leukemia 
(ATL), HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP), HTLV-I uveitis, and 
HTLV-I-associated infective dermatitis. In Japan, an estimated 1.2 million HTLV-I carriers have been 
identified, and more than 700 cases of adult T-cell leukemia (ATL) are diagnosed each year [2,3]. 
Since  the  initial  detection  and  isolation  of  HTLV-I,  HTLV  research  has  expanded  and  led  to  the 
development of more sensitive and specific methods of anti-HTLV-I antibody detection. In 1984, a 
cell membrane immunofluorescence assay was used to detect antibodies to the HTLV-I surface protein 
Env. A few years later, indirect immunofluorescent assays for HTLV p19 were developed [4,5]. In 1988, 
radioimmunoprecipitation assays (RIPA) were used to detect these antibodies in patients who had not 
tested positive by other immunofluorescent methods [6]. Eventually, enzyme-linked immunosorbent 
assays  (ELISA)  became  commonplace  in  anti-HTLV-I  antibody  detection,  as  well  as  the  use  of 
Western  Blots  (WB)  to  confirm  infectivity  [7,8].  More  recently,  we  have  developed  a  luciferase 
immunoprecipitation systems (LIPS) assay that has increased specificity and sensitivity in anti-HTLV-I 
antibody  detection  [9].  Collectively,  these  new  methodologies  have  helped  to  shed  light  on  the 
prevalence  of  the  virus,  indicating  that  approximately  15–20  million  individuals  worldwide  are 
infected with HTLV-I. Specifically, the virus is known to be endemic in Japan, several Caribbean 
countries, sub-Saharan Africa, South America, and areas of Iran and Melanesia.  
Among  diseases  associated  with  HTLV-I  is  a  chronic,  progressive,  neurodegenerative  disease 
termed HAM/TSP. Since the initial report of the association between HTLV-I and HAM/TSP, more 
associations  were  discovered  between  HTLV-I  and  diseases  including  HTLV-I  uveitis, 
bronchopneumonitis, arthritis, polymyositis, and various other inflammatory conditions [3,10,11]. As 
correlations of HTLV-I  with a range of medical conditions were being  demonstrated, information 
regarding the transmission of the virus was reported as well. HTLV-I infection requires cell-to-cell 
contact  with  infected  T  cells.  Transmission  may  occur  via  sexual  contact,  vertical  transmission 
(i.e., breast milk), and transfusion with infected blood [10–12]. Specifically, there is an increased risk 
for developing HAM/TSP associated with transfusion. In Japan, 20% of HAM/TSP patients reported a 
history of blood transfusion as opposed to 3% of normal donors (p < 0.001) [11].  
Due to this increased risk of disease with blood transfusion, many screening methods have been 
employed to detect HTLV-I infected donors. Blood bank screening for the virus was implemented in 
Japan in 1986, the United States in 1988, France in 1991, and the Netherlands in 1993 [10,11]. These 
screenings  were  initiated  once  proof  of  increased  risk  for  developing  HAM/TSP  was  definitively 
associated with transfusion. Numerous procedures exist for anti-HTLV-I antibody detection, including 
ELISA, RIPA, and particle agglutination. Standard screening assays used by blood banks in the United 
States  include  initial  testing  by  an  enzyme  immunoassay  (EIA),  followed  by  confirmation  of 
seropositivity by WB [12].  Viruses 2011, 3                         
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2. Defining and Identifying Seroindeterminates 
The WB used to confirm seropositivity in an  EIA positive patient sample utilizes recombinant 
proteins specific for HTLV-I/II Env glycoproteins incorporated into the WB strips. These recombinant 
proteins increase the sensitivity of the blot, as well as differentiate between HTLV-I and HTLV-II. 
The specific sensitivity of an EIA assay is approximately 95% and the EIA specificity averages 98% 
while the sensitivity of the WB is 97.1% with a specificity of 97.5% [13,14]. A sample is classified as 
HTLV-I positive if it meets the established criteria (see Figure 1). According to the World Health 
Organization,  an  HTLV-I  infected  individual  must  have  an  antibody  response  to  either  gp46  or 
gp62/68 (both Env protein bands) and either p19, p24, or p53 (one of the Gag bands). Even more rigid 
criteria has been recommended by the HTLV European Research Network, suggesting bands for both 
Gag proteins p19 and p24 as well as the Env proteins rgp21 and rgp46-I must be present to ensure 
seropositivity [15].  
Figure  1.  The  process  of  identifying  and  classifying  seroindeterminate,  negative,  and 
positive Human T-lymphotropic virus type I (HTLV-I) samples by enzyme immunoassay 
(EIA) testing and confirmatory Western blot (WB). 
 
 
Generally, HTLV-I infected individuals such as asymptomatic carriers, HAM/TSP patients, and 
ATL  patients  exhibit  the  clear  seropositivity  illustrated  in  Figure  2  on  the  HTLV  blot  2.4  (MP 
Diagnostics, Solon, OH, USA). However, there have been reports around the world of HTLV-I/II 
seroindeterminate WB banding patterns that do not meet the strict criteria of HTLV-I seropositivity 
[15–21]. These are referred to as HTLV-I/II seroindeterminates (see Figure 2, blots IND-1, IND-2, and 
IND-3). HTLV-I/II seroindeterminate samples have been identified in otherwise healthy and normal 
individuals from Jamaica, Japan, Brazil, and other HTLV-I endemic areas and showed no other sign of 
disease  or  viral  infection.  However,  of  particular  interest  are  the  reports  of  HTLV-I/II 
seroindeterminate blotting patterns in patients with various neurological diseases including Multiple Viruses 2011, 3                         
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Sclerosis [12,22]. While the significance of HTLV-I/II seroindeterminates is still under investigation, 
it is clear from this finding that these samples may relate to disease (specifically neurodegenerative 
diseases)  in  at  least  a  portion  of  cases.  The  reported  prevalence  of  seroindeterminates  has  varied 
greatly from .023% in Taiwan, to 0.1% in Argentina, to as high as 20% of a high-risk population in 
Brazil [18,23,24]. Interestingly, when DNA isolated from peripheral blood mononuclear cells (PBMC) 
of these HTLV-I/II seroindeterminate individuals is amplified using polymerase chain reaction (PCR) 
assays,  typically  no  HTLV-I  or  HTLV-II  virus  is  detected  (however,  recent  reports  from  Iran, 
Argentina, and Brazil have challenged this finding) [17]. A seroindeterminate sample is defined by a 
positive EIA result but an incomplete banding pattern by WB, as depicted in Figure 1 [16]. Incomplete 
banding  patterns  have  manifested  in  various  ways.  A  number  of  samples  yielded  all  core  protein 
bands,  but  lacked  one  or  both  of  the  recombinant  bands  (GD21  and  rgp46-I)  necessary  for 
seropositivity (for example, IND-2 in Figure 2). Other samples seemed to exhibit a negative blotting 
strip  except  for  a  single  protein  band  (as  shown  on  IND-3  in  Figure  2).  Classifying  a  blot  as 
seroindeterminate can vary greatly between studies and cohorts.  
Figure 2. The first two Western Blot strips depict positive control HTLV-I and HTLV-II 
Western Blots exhibiting all core bands necessary for seropositivity inclusion, and other 
bands  exhibited  in  a  typical  infected  sample.  IND-1  IND-2  and  IND-3  illustrate  three 
possible banding patterns of seroindeterminate samples.  
 Viruses 2011, 3                         
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3. Possible Explanations for HTLV-I/II Seroindeterminates  
As research progresses, reports of large numbers of HTLV-I/II seroindeterminates have come from 
Iran, Brazil, Japan, Argentina, Taiwan, the Caribbean, Central Africa, and the United States, indicating 
a  higher  prevalence  than  originally  thought  [15–21].  Importantly,  the  reasons  for  these  blotting 
patterns  remain  unclear.  Several  possible  explanations  have  been  proposed  for  the  occurrence  of 
HTLV-I/II seroindeterminates that include cross-reactivities to other known retroviruses or a novel 
virus, antibody responses to a malaria parasite with epitope homology to HTLV-I, a defective HTLV-I 
or  HTLV-II,  and  low  copy  numbers  of  prototypic  HTLV-I  in  the  affected  patient  yielding  the 
indeterminate antibody response. 
3.1. Malaria and Severe Acute Respiratory Syndrome (SARS) 
It has been reported that anti-HTLV-I reactivity of sera can result from antibodies produced in 
response to Plasmodium falciparum (P. falciparum). P. falciparum is a lethal malaria parasite and is 
the most prevalent of malaria parasites infecting humans [14]. Studies regarding this cross-reactivity 
concluded that P. falciparum and HTLV-I must contain regions of immunogenic epitope homology.  
It was hypothesized that this homology may be a result of mimicry of host tissue by the two organisms 
[25].  This  suggests  that  in  geographic  regions  known  to  be  endemic  for  malaria,  such  as  the 
Philippines,  and  in  which  high  levels  of  HTLV-I  antibody  reactivity  were  reported,  HTLV-I/II 
seroindeterminates  are  difficult  to  interpret,  as  it  is  difficult  to  rule  out  the  possibility  of 
cross-reactivity  between  HTLV-I/II  and  P.  falciparum  [25].  It  was  later  reported  that  this 
cross-reactivity might not be limited to P. falciparum. Examination of data from a separate cohort 
showed  cross-reactivity  with  HTLV-I  could  be  blocked  by  erythrocyte  lysates  (from  areas  where 
malaria is endemic) infected with P. falciparum, however HTLV-I seroindeterminate samples from the 
United States failed to block antibody reactivities. This led to the assertion that the molecular mimicry 
may  extend  to  epitopes  other  than  the  P.  falciparum  and  plasmodial  antigens  [26].  However, 
HTLV-I/II  seroindeterminate  banding  patterns  are  being  reported  in  areas  where  exposure  to 
P. falciparum  is  extremely  unlikely,  such  as  the  United  States.  Furthermore,  HTLV-I/II 
seroindeterminate patterns are observed in normal, healthy blood donors, showing no sign of malaria 
or similar parasite infection [20]. While a subset of HTLV-I/II seroindeterminate samples may exhibit 
an antibody cross-reaction between HTLV-I and P. falciparum, this cannot explain the WB banding 
patterns found in areas where these organisms are extremely rare or nonexistent.  
It should also be noted that cross-reactivity between antibodies against severe acute respiratory 
syndrome (SARS) coronavirus and HTLV has been observed on occasion [27]. The HTLV antibody 
response  was  exhibited  when  numerous  serology  tests  were  performed  on  samples  from  patients 
admitted to a hospital in Taiwan for SARS. However, this was immediately  following the SARS 
outbreak in 2003, and has not been observed in other regions. 
3.2. Cross-Reactivities to Other Retrovirus  
Various  other  hypotheses  have  been  presented  regarding  the  cross-reactivity  of  anti-HTLV-I 
antibodies.  In  1997,  it  was  reported  that  HTLV  I/II  indeterminate  serologies  were  observed  as Viruses 2011, 3                         
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responses to two types of simian T-lymphotropic virus (STLV) [28]. An HTLV-I/II seroindeterminate 
sample that was also HTLV-I PCR positive was sequenced and showed a divergent form of HTLV-I 
[28]. Further investigations led to the suggestion that indeterminate blots may denote an antibody 
response  to  immunogenic  regions  of  an  endogenous  retrovirus  [29].  Also  reported  was  the 
demonstration of elevated antibody levels to synthetic HTLV-I epitopes in samples previously testing 
negative for HTLV-I antibodies. The reactivity in this study reinforced a previous suggestion that 
increased levels of HTLV-I antibodies may be an autoantibody response to the endogenous retrovirus 
HRES-I  [30,31].  The  specific  homologous  regions  between  HTLV-I  and  these  endogenous 
retroviruses occur in the LTR, gag, and pol regions of the virus. However, a later report demonstrated 
the tax region of prototype HTLV-I virus was amplified by nested PCR from one patient with an 
HTLV-I/II seroindeterminate WB that could not have been derived from the DNA sequence of an 
endogenous  virus  [12].  HTLV-I/II  seroindeterminate  banding  patterns  have  also  been  reported  in 
samples which were PCR positive for HTLV-I, supporting the exciting possibility that an HTLV-I/II 
seroindeterminate pattern may result from cross-reactivity with a novel virus such as HTLV-III or 
HTLV-IV  [32].  These  newly  discovered  human  retroviruses  were  found  in  Cameroonese  hunters 
showing  no  signs  of  HTLV-related  diseases,  and  all  four  HTLV  types  show  60–70%  sequence 
homology with each other [31].  
3.3. Low Copy Number of Prototype HTLV-I 
Due to the typically negative PCR results and lack of antibody response to some of the HTLV-I 
antigens  but  reactivity  to  others,  the  most  plausible  suggestions  seems  to  be  that  HTLV-I/II 
seroindeterminate  blots  may  result  from  a  low  copy  number  of  prototypic  HTLV-I  [12].  This 
explanation  is  supported  by  studies  showing  the  ability  to  amplify  the  HTLV-I  tax  region  from 
PBMCs of some HTLV-I/II seroindeterminates, but not other regions of the virus [12,28,29]. The 
same study reported the successful generation of an Epstein-Barr virus transformed B-cell line from a 
relapsing remitting multiple sclerosis patient with a seroindeterminate WB. The PBMCs from this 
patient had tested negative for regions of HTLV-I by PCR, while an in vitro long-term generated 
B-cell line tested positive by primary PCR. The virus infecting the seroindeterminate B cell line was 
then sequenced in an attempt to identify any mutations or other factors that may be associated with an 
HTLV-I/II  WB  seroindeterminate  status.  The  results  indicated  that  the  virus  was  globally  >97% 
homologous to prototypic HTLV-I on the nucleotide level. Fine analysis of the 5′ LTR indicated that 
the HTLV-I strain infecting the patient was of  the Cosmopolitan subtype [22]. This was the first 
reported verification of a PCR negative seroindeterminate sample resulting from infection of a full 
length HTLV-I virus [22]. Further support for the suggestion that these seroindeterminates may be the 
result of a low copy number of prototype HTLV-I comes from a study of patients transfused with 
HTLV-1 infected blood [33]. Eight seronegative individuals developed seroindeterimnate WB patterns 
after receiving a blood transfusion with the infected blood, further implicating the role of exposure to 
HTLV-I in seroindeteriminates [33].  
The hypothesis that HTLV-I/II WB seroindeterminates (or subsets of these individuals) may be 
related to prototype HTLV-I is further supported by the recent observations that demonstrated HTLV-I 
PCR positive results in 12.5% of HTLV-I/II seroindeterminates from Iran [17] (Table 1). Consistent Viruses 2011, 3                         
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with this observation are reports from Brazil and Argentina, which also demonstrated comparable rates 
of PCR reactivity in HTLV-I/II seroindeterminates (9.2% and 13.8%, respectively) [17] (Table 1). The 
most prevalent seroindeterminate banding pattern observed in Iran was the appearance of GD21 alone, 
which  is  similar  to  the  patterns  seen  in  Taiwan  [27,34].  The  data  in  Table1  also  demonstrates  a 
relatively high frequency of HTLV-I/II WB seroindeterminates from HTLV-I EIA reactive samples 
that are observed in multiple cohorts throughout the world. These range from 16% in the United States 
to 61% in Argentina. Reports of PCR amplification of prototype HTLV-I sequences from HTLV-I/II 
seroindeterminate  individuals,  especially  in  endemic  regions  such  as  Iran  and  Brazil,  suggest  a 
potentially  far  greater  exposure  to  HTLV-I  at  least  in  some  sub-populations  of  HTLV-I/II  WB 
seroindeterminates.  
Table  1.  The  table  illustrates  the  prevalence  of  Human  T-lymphotropic  virus  type  I 
(HTLV-I) in various cohorts, as well as the percentage of HTLV-I Western blot (WB) 
seroindeterminates in the respective cohort and the percentage of these seroindeterimates 
that were HLTV-I PCR positive.  
Country 
[Reference] 
Number 
Screened 
HTLV-I 
EIA 
Reactive 
HTLV-I WB + 
(% of Total 
EIA Reactive) 
HTLV-II WB + 
(% of Total 
EIA Reactive) 
WB 
Seroindeterminate 
(% of Total EIA 
Reactive) 
* HTLV-I PCR + 
(% of WB 
Serondeterminates) 
Argentina 
[17] 
86,238  0.17%  20%  8.0%  61%  13.8% 
Brazil [19]  351,639  1.22%  24%  Not Shown  52.2%  9.2% 
Iran [17]  79,687  6.4%  50.7 %  3.1%  25.4%  12.5% 
Taiwan [35]  1,122,879  0.1%  41%  1.0%  22%  Not Shown 
US [36]  267,650  0.89%  3%  Not Shown  16%  0.00% 
* PCR results were obtained from a subset of WB Indeterminate samples for each cohort, as all samples were 
not available for further analysis. 
4. Current Research and Future Directions  
While the significance of these prevalent seroindeterminate HTLV-I/II blotting patterns remains 
uncertain, it is clear that further investigation is necessary. The sequencing of a virus with homology to 
prototype HTLV-I from a seroindeterminate cell line implicates exposure to the virus in at least some 
HTLV-I/II  seroindeterminates.  This  finding  may  suggest  that  exposure  to  HTLV-I  is  greater  than 
previously estimated. Of concern are reports that have demonstrated serum samples with negative 
HTLV-I/II results by EIA, which may also have seroindeterminate banding patterns by WB [12]. Since 
these sera were initially screened as HTLV-I/II EIA negative (see Figure 1), these samples (that also 
have an HTLV-I/II seroindeterminate WB pattern) would enter the blood supply and be available for 
transfusion  [37].  There  have  also  been  instances  of  serum  samples  testing  EIA  positive  and  WB 
indeterminate at one point in time, and later testing EIA negative, while remaining seroindeterminate 
by  WB  [33].  This  implies  testing  at  one  time  point  by  EIA  cannot  ensure  the  exclusion  of 
seroindeterminate samples. If seroindeterminate blotting patterns are a result of infection or exposure 
to  HTLV-I  (a  virus  associated  with  neurodegenerative  disease,  among  other  illnesses),  and  blood Viruses 2011, 3                         
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samples with these patterns can be negative by EIA screening and enter the blood supply, this poses a 
possible  risk  to  those  transfused  with  HTLV-I/II  seroindeterminate  blood  although  the  clinical 
consequence of obtaining blood from an HTLV-I/II WB seroindeterminate donor is not known. Based 
on these observations there is a need for more stringent screening techniques for blood banks to ensure 
blood from seroindeterminate donors is not transfused. Increasingly sensitive and specific assays are 
currently being optimized to better detect anti-HTLV-I antibody responses.  
One  such  technique  is  LIPS  assay.  The  LIPS  assay  yields  high  throughput  results  while  also 
generating  quantitative  values  of  anti-HTLV-I  antibody  responses  [9].  This  creates  data  for 
quantitative cohort comparison as well as allows for differentiation between HTLV-I infected disease 
patients  and  asymptomatic  HTLV-I  carriers  and  the  possible  generation  of  a  risk  assessment  for 
disease development. Using antibody responses to the immunogenic epitopes of HTLV-I, Gag, Env 
and Tax, LIPS produces clear quantitative values for asymptomatic carriers, HAM/TSP patients, ATL 
patients, and may yield similar results for seroindeterminate individuals. The plasmids used in the 
LIPS assay are inserted with a gene including immunogenic epitope of a virus (for example, the gag, 
env, or tax region of HTLV-I). Renilla luciferase-fusion proteins (Ruc-antigen) are obtained from cell 
lysates transfected with each plasmid. A preincubated serum/antigen mixture is added to a filter plate 
coated  with  immobilized  protein  A/G  beads.  This  mixture  is  then  washed  to  remove  any  fusion 
proteins  that  did  not  bind  to  the  antibody.  Luciferase  activity  is  then  measured  in  a  microplate 
luminometer.  
Figure 3. The process of antibody profiling by the luciferase immunoprecipitation systems 
(LIPS) assay. 
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The LIPS assay provides a promising high throughput method of anti-HTLV-I antibody detection. 
Further  examination  of  immunogenic  epitopes,  such  as  HTLV-I  Rex  and  HBZ,  may  enhance  the 
specificity  and  sensitivity  of  the  assay.  Currently,  a  whole  Gag  protein  is  used  for  detection  of 
antibody response; however, antibody responses for p19, p24, or other portion of the Gag protein may 
yield even more specific results. A panel of these quantitative antibody responses may be able to 
detect seroindeterminate samples in a fast, inexpensive, and efficient manner. LIPS may also detect 
seroindeterminates  that  tested  negative  by  EIA,  proving  to  be  a  more  sensitive  assay  in  terms  of 
seroindeterminate detection. While the LIPS assay is under further development, other methods to 
improve  detection  and  classification  of  seroindeterminates  have  also  been  proposed  including: 
real-time PCR, molecular diagnostic analysis, detection of amino acid changes in the env region of 
HTLV-I, inclusion of other synthetic peptides in serological assays, and optimization of an enzyme 
oligonucleotide assay (EOA) [19,37–39].  
With  further  in  depth  research  involving  these  newer  methodologies,  the  significance  of  these 
HTLV-I/II seroindeterminate banding patterns will become clearer. As it becomes apparent that the 
prevalence of seroindeterminates is more widespread than originally thought, it becomes increasingly 
important to clarify the meaning of these results. If HTLV-I/II seroindeterminates (or subsets of these 
subjects)  represent  exposure  to  prototype  HTLV-I  or  HTLV-II,  the  frequency  of  infection  in  the 
general  population  will  be  greater  than  previously  believed.  It  remains  to  be  seen  whether  the 
incidence of exposure is also associated with any clinical disease outcome.  
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